Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

t SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human cancers, including JAK2, RON, ALK, RAS and IKKe. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to research and development programs, plans for 2008 and beyond, expectations regarding the nomination of development candidates and the timing of the filing of INDs and commencement and success of IND enabling activities and preclinical and clinical studies, partnership opportunities, the potential of the Company's inhibitors as treatments for certain cancers, the potentially distinct properties of the Company's compounds, partnering opportunities for the Company's research and development programs and the ability to discover, develop, build a pipeline of and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery,
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... Calif. , May 23, 2013 ... a strategic alliance with DAK Renewable Research to ... corn oil yield. VG Energy is a majority ... Pink: VGLS). VG Energy,s exclusively licensed ... increase the oil yield in plants, possessing a ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3
... DENVER, Colorado and JERUSALEM, September 16 ... Venture announced today,that Children,s Hospital is enrolling patients for ... series of cord blood transplant sites,worldwide, five of which ... Spain, Italy, Hungary and Israel. The trial is researching ...
... ... Precision and Reduce Risk of False Positives/Negatives , ... Rochester, NY (PRWEB) September 16, 2009 -- iCardiac Technologies, ... that a top 15 pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. ...
... ST. LOUIS, Sept. 15 Sigma-Aldrich Corporation (Nasdaq: SIAL ... on Monday, September 21st at 8:30 AM Eastern Daylight Time in ... over the Internet available at http://investor.sigmaaldrich.com/ . Users ... , About Sigma-Aldrich: Sigma-Aldrich is ...
Cached Biology Technology:Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4Top 15 Pharmaceutical Company Awards Cardiac Safety Study to iCardiac 2
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
(Date:5/23/2013)... prostate cancer patients unnecessarily undergo surgery or harsh ... between slow-growing and aggressive forms of the disease. ... Hopkins Medical Institutes are developing technology that allows ... for relatively mild treatments or take drastic measures. ... Madabhushi, an associate professor of biomedical engineering at ...
(Date:5/23/2013)... in Neuron , the team reveal the interplay ... work funded by the Wellcome Trust and BBSRC. ... stimuli we improve our perceptual abilities. While these changes ... can also affect the fidelity of that response. ... Neuroscience explains: "When you communicate with others, you can ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... Researchers at the La Jolla Institute for Allergy & Immunology ... -- the specific immune system T cells which trigger the ... finding is an important advance that verifies in humans several ... key focal point for interrupting the disease process. "This ...
... Chris Austin recently discovered two new species of frogs in ... known vertebrate, averaging only 7.7 millimeters in size less ... , an Indonesian fish averaging more than 8 millimeters, from ... United States including LSU graduate student Eric Rittmeyer, made the ...
... new information on one of the most critical protein ... team of researchers with the U.S. Department of Energy,s ... of California (UC) Berkeley. The researchers have provided the ... by the protein machines known as proteasomes to identify ...
Cached Biology News:La Jolla Institute researchers identify pivotal immune cell in Type 1 diabetes in humans 2La Jolla Institute researchers identify pivotal immune cell in Type 1 diabetes in humans 3LSU professor discovers world's tiniest vertebrate 2New information on the waste-disposal units of living cells 2New information on the waste-disposal units of living cells 3
Auto/Zyme Reagent...
HistoScan HRP Kit Universal Goat Kit...
Interact with both DNA and RNA; fluorescence green (Em=525 nm) bound to DNA; and fluorescence red (Em=~650 nm) bound to RNA....
...
Biology Products: